New financial targets set: organic growth above 8%, EBITA margin above 12%, and return on capital employed above 15%. Strategic focus is on value chain expansion, sustainability, and innovation, with major investments in drug delivery and materials, supported by a strong global footprint.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.